记者丨黎雨桐 见习记者林健民 6日，A股三大指数高开，截至9：50左右，沪指报4054.25点，突破2025年11月14日的阶段高点，刷新 2015年7月底以来的新高。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ | 上证指数 深证成指 | 科创综指 | | --- | --- | | 4054.25 13946.42 | 1723.70 | | +30.83 +0.77% +117.79 +0.85% +27.86 +1.64% | | | 创业板指 万得全A | 北证50 | | 6599.79 3318.62 | 1482.88 | | +61.85 +0.95% +24.07 +0.73% +16.46 +1.12% | | | 沪深300 中证500 | 中证A500 | | 4762.71 7745.80 | 5823.89 | | +44.97 +0.95% +94.61 +1.24% +60.59 +1.05% | | | 中证1000 深证100 | 中证红利 | | 7818.17 5966.20 | 5538.87 | | +64.29 +0.83% +37 ...

早盘，人脑工程板块表现活跃。板块内11只个股涨停。三博脑科、翔宇医疗、爱朋医疗、美好医疗 20CM涨停，伟思医疗涨超19%，麦澜德、诚益通涨超14%，熵基科技涨超12%，道氏技术、博拓生物 涨超10%，创新医疗、普利特、岩山科技、塞力医疗、盈趣科技、南京熊猫、国际医学涨停。 消息面上，马斯克旗下Neuralink宣布将在2026年启动脑机接口设备大规模生产，同步推进流程高度精 简、几乎完全自动化的手术方案，电极丝可直接穿过硬脑膜无需切除，有效规避传统侵入式设备的创伤 性瓶颈，实现效率与成本的双向优化。 同时，OpenAI首席执行官Sam Altman参与创立的脑机接口初创公司MergeLabs完成分拆独立，将专注于 超声波读取脑部活动技术研发，无需植入电极即可大范围解读大脑信号，为脑机接口应用提供全新技术 路径。 脑机接口核心技术研发：作为人脑工程的核心赛道，掌握信号采集、算法处理等核心技术的企业将率先 受益于行业技术迭代与商业化落地。随着侵入式与非侵入式技术同步推进，具备自主研发能力、拥有技 术壁垒的企业将抢占市场先机，分享行业高速增长红利。 医疗设备制造：脑机接口的商业化应用需要大量定制化医疗设备支持，包 ...

Core Viewpoint - A-shares have experienced a significant rally, with the Shanghai Composite Index reaching a new high not seen since July 2015, indicating strong market sentiment and potential for continued growth in the technology sector [1][4]. Market Performance - As of the latest data, the Shanghai Composite Index is at 4054.25, up by 30.83 points (+0.77%), while the Shenzhen Component Index and the Sci-Tech Innovation Index also showed positive movements [2]. - The A-share market has achieved a remarkable 12 consecutive days of gains, marking the longest streak since 1993, with previous records being 11 consecutive days in 2006 and 2017-2018 [3]. Sector Highlights - The brain-computer interface sector is witnessing explosive growth, with companies like Xiangyu Medical and Aipeng Medical hitting the 20% daily limit up [2]. - Other notable performers include Meihua Medical, Innovation Medical, and Aerospace Changfeng, all showing significant percentage increases [3]. Future Outlook - Analysts from Dongzheng Futures and Debon Securities suggest that the current market sentiment is optimistic, with expectations for a "slow bull" market trend to continue, particularly in technology stocks [4][5]. - The report indicates that sectors such as commercial aerospace, artificial intelligence, and robotics are expected to remain in focus, alongside cyclical sectors like oil and non-ferrous metals [5]. Hong Kong Market Performance - In the Hong Kong market, tech stocks are also performing well, with JD Health rising over 6% and other companies like XPeng and NetEase seeing gains of over 3% [5][6].

Core Insights - The medical device sector is experiencing a strong upward trend, with the CSI All Index Medical Device Index rising by 1.25% and significant gains in key stocks such as Meihua Medical and Xiangyu Medical reaching the daily limit of 20% [1] - Neuralink, owned by Elon Musk, plans to begin large-scale production of brain-machine interface devices in 2026, aiming for a streamlined and automated surgical process, with the goal of helping paralyzed individuals regain full body function [1] - The brain-machine interface has been included in China's 14th Five-Year Plan, with specific targets set for technological breakthroughs by 2027 and industry strength to rank among the world's top by 2030 [1] Industry Developments - Domestic high-end medical device market share is increasing, with over 70% penetration of domestic DR and ultrasound diagnostic equipment in grassroots medical institutions, and rising application rates of high-end CT and MRI in tertiary hospitals [2] - The brain-machine interface industry is expected to enter a growth phase due to policy support, accelerating the transition from research to commercialization [2] - The brain-machine interface market is projected to grow at a CAGR of 17% from 2025 to 2034, reaching an estimated market size of $12.4 billion by 2034 [2] ETF Insights - The medical device ETF (159883) has the highest exposure to brain-machine interfaces, accounting for over 23% of its holdings, and is the largest ETF focused on the medical device sector [3] - The Hong Kong medical ETF (159366) tracks the CSI Hong Kong Stock Connect Medical Theme Index, providing access to high-quality assets in the medical device and biotechnology sectors [3] - Both ETFs are positioned to benefit from the growth in domestic innovation, export acceleration, and new technology advancements in the medical device industry [3]

Core Insights - The medical device sector is experiencing a strong upward trend, with the CSI All Index Medical Device Index rising by 1.25% and significant gains in key stocks such as Meihua Medical and Xiangyu Medical [1] - Neuralink, owned by Elon Musk, plans to begin large-scale production of brain-machine interface devices in 2026, aiming for a streamlined and automated surgical process [1] - The brain-machine interface has been included in China's 14th Five-Year Plan, with specific goals for technological breakthroughs by 2027 and industry strength by 2030 [1] Market Performance - The medical device ETF (159883) has seen a 1.16% increase, with net subscriptions exceeding 400 million units [1] - The latest net inflow into the medical device ETF is 274 million yuan [1] Industry Developments - Domestic high-end medical device market share is increasing, with over 70% penetration of domestic DR and ultrasound diagnostic equipment in grassroots medical institutions [2] - The brain-machine interface industry is expected to enter a growth phase, transitioning from research to commercialization, supported by policy and technological advancements [2] - The brain-machine interface market is projected to grow at a CAGR of 17% from 2025 to 2034, reaching an estimated $12.4 billion by 2034 [2] ETF Insights - The medical device ETF (159883) has the highest brain-machine interface content in the market, accounting for over 23% of its holdings, and focuses on innovative domestic companies [3] - The Hong Kong medical ETF (159366) tracks a medical theme index, providing exposure to high-quality assets in the medical device sector, including minimally invasive brain science and robotics [3]

北京商报讯（记者 丁宁）1月6日，延续前一交易日大涨走势，人脑工程板块涨幅明显。 具体来看，三博脑科、美好医疗开盘"20cm"涨停，爱朋医疗、翔宇医疗等高开超10%。 ...

Core Insights - The announcement by Elon Musk regarding Neuralink's mass production of brain-machine interface (BMI) devices has significantly boosted market confidence in the commercialization of this technology, leading to a surge in related A-share stocks on the first trading day of 2026 [2][3][10] Group 1: Market Reaction - On January 5, 2026, domestic BMI concept stocks collectively opened high, with companies like Beikang rising over 29.98% and several others hitting the daily limit of 20% [1] - The market's positive response reflects high expectations for the commercial prospects of brain-machine interfaces following Musk's announcements [2][3] Group 2: Neuralink's Developments - Neuralink has completed seven rounds of financing, raising over $1.3 billion, which is significant compared to the projected $2.9 billion global market size for BMIs in 2025 [3][4] - The company has achieved several milestones, including FDA approval for human clinical trials and the first human implantation of a BMI, marking its leadership in the field [3][4] Group 3: Clinical Advancements in China - 2025 was termed the "Year of Chinese Brain-Machine Interfaces," with numerous clinical breakthroughs in restoring motor and speech abilities for high-level paraplegics, visual reconstruction, and treatment of mental disorders [7][8][10] - Key clinical trials have been conducted by various institutions, demonstrating significant advancements in BMI technology and its applications [9] Group 4: Regulatory and Market Developments - The introduction of policies such as the inclusion of BMIs in medical insurance and the establishment of regulatory frameworks for BMI medical devices indicate a move towards commercialization [10] - In 2025, the Chinese BMI sector saw 24 financing rounds, a 30% increase year-on-year, signaling growing investor interest and confidence in the market [10] Group 5: Competitive Landscape - Despite the surge in stock prices, there are currently no pure-play BMI companies listed in China, with many firms still in the process of developing their products and seeking IPO opportunities [11][12] - Companies like Qiangnao Technology and Bori Kang are actively pursuing IPOs, indicating a competitive race to become the first publicly listed BMI company in China [12][13] Group 6: Future Outlook - The industry is expected to enter a commercialization phase in 2026, with a competitive landscape emerging as various companies aim to establish themselves in the market [14]

记者丨易妍君 编辑丨张星 2026年，A股旗开得胜，三大股指在首个交易日（即1月5日）悉数上涨。 这一天，上证指数重返4000点之上，日线更是迎来罕见的12连阳，为"春季躁动"预期下的A股市场再添"一把火"。 市场热点轮番活跃，脑机接口、保险、存储器等题材相对强势；CRO、模拟芯片、基因检测、虚拟人等概念也有不错的表现。 展望后市，前海开源基金首席经济学家、基金经理杨德龙判断，2026年科技牛行情有望延续。 多因素助推A股"开门红" 1月5日，A股市场高开高走，喜迎2026年"开门红"。 截至当日收盘，上证指数涨1.38%，报4023.42点；深证成指涨2.24%，报13828.63点；创业板指的涨幅接近2.9%，报3294.55点。科 创50指数则大涨4.41%，北证50指数上涨1.8%。 当天，全部A股成交额达2.57万亿元，较前一个交易日增加了5000多亿元。全市场近4200只个股上涨。 在业内人士看来，A股"开门红"得益于多重积极因素的共振。 "节后市场情绪在假期港股走强的带动下显著回暖； 资金层面，市场对年内保险资金等长期增量资金入市抱有期待，同时全球流动 性宽松预期也提振了风险偏好；更深层次的驱动 ...

Core Viewpoint - The A-share market started 2026 on a positive note, with all three major indices rising, indicating a shift from valuation recovery in 2025 to profit-driven growth in 2026 [1][5]. Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to 4023.42 points, the Shenzhen Component Index increased by 2.24% to 13828.63 points, and the ChiNext Index saw a rise of nearly 2.9% to 3294.55 points [5]. - The total trading volume reached 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [5]. Sector Highlights - Key sectors showing strong performance included brain-computer interfaces, insurance, and storage devices, with significant gains in AI applications and emerging industries [2][6]. - The brain-computer interface sector experienced a surge, with related stocks hitting the daily limit, driven by news from overseas about Neuralink's plans for large-scale production [7][9]. Investment Outlook - Analysts predict that the 2026 technology bull market is likely to continue, with a focus on sectors such as technology growth, advanced manufacturing, and cyclical consumption [2][12]. - Investment strategies for 2026 include a balanced approach of high-quality stocks and high-potential sectors, emphasizing technology companies with strong fundamentals and emerging industries [13]. Structural Opportunities - The pharmaceutical sector is expected to see structural opportunities driven by innovation, international expansion, and policy reforms, with a focus on innovative drugs and AI integration in healthcare [14].

Core Viewpoint - The A-share market experienced a significant surge in brain-computer interface (BCI) stocks, driven by Elon Musk's announcement regarding Neuralink's plans for large-scale production in 2026, indicating a shift towards commercialization of BCI technology [1][2][4] Group 1: Market Performance - On the first trading day of 2026, multiple BCI-related stocks hit their daily limit, with companies like Beikang rising by 30% and others such as Sanbo Brain Science and DiNaiKe increasing by 20% [1][2] - A total of 52 BCI concept stocks closed higher, with over 40 stocks reaching their daily limit, showcasing strong market enthusiasm [2] Group 2: Technological Advancements - Neuralink's announcement includes plans for a streamlined and automated surgical process for BCI devices, which could reduce the invasiveness of traditional methods [2][4] - The company has successfully implanted its BCI devices in 12 individuals, with a total usage time exceeding 15,000 hours, demonstrating the technology's potential for controlling physical devices [3] Group 3: Industry Outlook - The BCI market is projected to exceed $10 billion by 2030, with long-term estimates suggesting it could reach approximately $124 billion by 2034, driven by advancements in technology and integration with AI and robotics [6] - The Chinese government has identified BCI as a future industry in its "14th Five-Year Plan," indicating strong policy support for the sector [6] Group 4: Competitive Landscape - Companies like Qiangnao Technology are emerging as leaders in non-invasive BCI solutions, with a focus on various applications such as insomnia and autism intervention [5] - The market for non-invasive BCI products currently holds an 82% share globally, indicating a significant opportunity for growth in this segment [5]